Department of Pediatric Nephrology, Tokyo Metropolitan Children's Hospital, Umezono 1–3–1, Kiyoseshi, Tokyo 204-8567, Japan.
Pediatr Nephrol. 2010 Jan;25(1):75-81. doi: 10.1007/s00467-008-0982-z.
Encapsulating peritoneal sclerosis (EPS) is the most serious complication of long-term peritoneal dialysis (PD), with a mortality rate that exceeds 30%. There have been many reports of the incidence of EPS being strongly correlated to the duration of PD. Patients on PD for longer than 5 years, and especially those receiving this treatment for more than 8 years, should undergo careful and repeated surveillance for risk factors associated with the development of EPS. The development of ultrafiltration failure, a high dialysate/plasma creatinine ratio, as determined by the peritoneal equilibration test, peritoneal calcification, a persistently elevated C-reactive protein level, and severe peritonitis in patients on PD for longer than 8 years are signals that should prompt the clinician to consider terminating PD as a possible means of preventing the development of EPS. The impact of the newer, biocompatible PD solutions on the incidence of EPS has not yet been determined.
包裹性腹膜硬化症（EPS）是长期腹膜透析（PD）最严重的并发症，其死亡率超过 30%。有许多报告表明，EPS 的发病率与 PD 的持续时间密切相关。PD 治疗时间超过 5 年的患者，尤其是接受 PD 治疗超过 8 年的患者，应仔细并反复监测与 EPS 发展相关的危险因素。对于 PD 治疗时间超过 8 年的患者，如果出现超滤衰竭、腹膜平衡试验显示透析液/血浆肌酐比值高、腹膜钙化、持续升高的 C 反应蛋白水平和严重腹膜炎，这些都是提示临床医生考虑终止 PD 的信号，以预防 EPS 的发生。新型生物相容性 PD 溶液对 EPS 发生率的影响尚未确定。
